How would you approach a middle-aged female, non-smoker diagnosed with stage 1-B lung adenocarcinoma in which the FoundationOne CGP identified a TRIM33-RET fusion?

How would you approach a middle-aged female, non-smoker diagnosed with stage 1-B lung adenocarcinoma in which the FoundationOne CGP identified a TRIM33-RET fusion?

How would you approach a middle-aged female, non-smoker is diagnosed with stage 1–B lung adenocarcinoma in which the FoundationOne CGP identified a TRIM33–RET fusion. What would be the “target-focused” treatment and timing implications of this finding?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Alexander Drilon, MD

Alexander Drilon, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY, USA